Effects of Angiotensin Converting Enzyme (ACE) inhibitors versus candesartan in reducing cardiovascular events in primary treatment of hypertension - ARBACE
Study identifier:NIS-CSE-ATA-2010/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Effects of Angiotensin Converting Enzyme inhibitors vs candesartan in reducing cardiovascular events in primary treatment of hypertension
Medical condition
hypertension
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
50000
Study type
Observational
Age
17 Years +
Date
Study Start Date: 01 Jun 2010
Primary Completion Date: 01 Nov 2010
Study Completion Date: 01 Nov 2010
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| ACE Patients treated for hypertension with ACEs without CVD | - |
| Candesartan Patients treated for hypertension with candesartan without CVD | - |
Contacts
Investigators
Principal Investigator
Niklas Lindarck
AstraZeneca Nordic
